Overview

Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Enzastaurin in Vascular Ehlers-Danlos Syndrome.

Status:
Not yet recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy of enzastaurin compared to placebo in preventing arterial events (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) leading to intervention or mortality attributable to an arterial event in patients with vEDS confirmed with pathogenic heterozygous COL3A1 gene mutations predicted to derive a mutant protein.

Phase:

Phase 3

Details

Lead Sponsor:

Aytu BioPharma, Inc.

Collaborator:

Parexel